Biotechnology company and drug delivery platform
innovator Lexaria Bioscience
(CSE: LXX) (OTCQX: LXRP) today announced successful completion of its
Master Collaborative Research Agreement (“the R&D Program”) with the
National Research Council of Canada (“NRC”). The R&D program sought to
investigate technical aspects and new opportunities associated with bioavailability
enhancement of lipophilic active ingredient compositions using Lexaria’s
patented DehydraTECH(TM) technology with a primary goal to determine whether,
through its processing, DehydraTECH causes the formation of a new molecular
entity (“NME”). According to the update, all evidence aligns to confirm that no
covalent-bonded NME is created with Lexaria’s technology. Processes or
technologies that do create an NME, including certain forms of nanotechnology,
often face much more extensive regulatory hurdles from agencies, such as the
FDA or Health Canada, to prove that the NME is safe for human consumption.
To view the full press release, visit http://ibn.fm/tZa21
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. has developed and out-licenses its
disruptive delivery technology that promotes healthier ingestion methods, lower
overall dosing and higher effectiveness of lipophilic active molecules. Lexaria
has multiple patents pending in over 40 countries around the world and has
patents granted in the USA and in Australia for utilization of its
DehydraTECH(TM) delivery technology. Lexaria’s technology provides increases in
intestinal absorption rates; more rapid delivery to the bloodstream; and important
taste-masking benefits, for orally administered bioactive molecules including
cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs),
nicotine and other molecules. For more information, visit the company’s website
at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
